Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 2/20 | 0.42 |
| ▸ | BRD2 | P25440 | 1/20 | 0.42 |
| ▸ | PTGS1 | P23219 | 4/20 | 0.41 |
| ▸ | PTGS2 | P35354 | 4/20 | 0.41 |
| ▸ | TDO2 | P48775 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 5/20 | 0.38 |
| ▸ | RAB9A | P51151 | 5/20 | 0.38 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.38 |
| ▸ | NFKB2 | Q00653 | 2/20 | 0.38 |
| ▸ | RELA | Q04206 | 2/20 | 0.38 |
| ▸ | CASP3 | P42574 | 1/20 | 0.37 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.37 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.37 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.37 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 3/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2092874 | 0.77 | NR1H4 (0.42) | BRD4BRD2PTGS1PTGS2NPC1 | |
| SCHEMBL314833 | 0.67 | BRD4 (0.47) | BRD4BRD2PTGS1PTGS2TDO2 | |
| SCHEMBL1398770 | 0.62 | NPC1 (0.38) | BRD4BRD2PTGS1PTGS2NPC1 | |
| SCHEMBL637899 | 0.62 | ALDH1A1 (0.36) | BRD4BRD2PTGS1PTGS2TDO2 | |
| SCHEMBL854952 | 0.61 | TDO2 (0.36) | BRD4BRD2PTGS1PTGS2TDO2 | |
| Biphenyl SCHEMBL15648861 | 0.59 | ALDH1A1 (0.53) | BRD4BRD2NPC1RAB9ANFKB1 | |
| SCHEMBL21105338 | 0.58 | BRD4 (0.68) | BRD4BRD2PTGS1PTGS2TDO2 | |
| SCHEMBL21105084 | 0.58 | PTGS1 (0.55) | BRD4BRD2PTGS1PTGS2MEN1 | |
| Biphenyl SCHEMBL10535512 | 0.58 | ALDH1A1 (0.60) | BRD4BRD2NPC1RAB9ANFKB1 | |
| Toluene SCHEMBL27476235 | 0.58 | ACHE (0.73) | BRD4BRD2NPC1RAB9ANFKB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 54 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3089980-B1 | SERINE/THREONINE KINASE INHIBITORS | ARRAY BIOPHARMA INC (US) | 2018-01-31 | — | — | EP | claimed |
| EP-2200440-B1 | ANTIBACTERIAL AMIDE AND SULFONAMIDE SUBSTITUTED HETEROCYCLIC UREA COMPOUNDS | CRESTONE INC (US) | 2017-07-19 | — | — | EP | claimed |
| US-9670208-B2 | Serine/threonine kinase inhibitors | ARRAY BIOPHARMA INC. (US) | 2017-06-06 | — | — | US | claimed |
| EP-3089980-A1 | SERINE/THREONINE KINASE INHIBITORS | Array Biopharma, Inc. (US) | 2016-11-09 | — | — | EP | claimed |
| US-20160304519-A1 | SERINE/THREONINE KINASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2016-10-20 | — | — | US | claimed |
| WO-2015103137-A1 | SERINE/THREONINE KINASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2015-07-09 | — | — | WO | claimed |
| US-8148380-B2 | Antibacterial amide and sulfonamide substituted heterocyclic urea compounds | CRESTONE, INC. (US) | 2012-04-03 | — | — | US | claimed |
| US-20120015941-A1 | Antibacterial Amide and Sulfonamide Substituted Heterocyclic Urea Compounds | CRESTONE, INC. (US) | 2012-01-19 | — | — | US | claimed |
| US-20110118234-A1 | Urea Compounds as Gamma Secretase Modulators | AMGEN INC. | 2011-05-19 | — | — | US | claimed |
| EP-2300427-A1 | UREA COMPOUNDS AS GAMMA SECRETASE MODULATORS | AMGEN INC. (US) | 2011-03-30 | — | — | EP | claimed |
| EP-2200440-A1 | ANTIBACTERIAL AMIDE AND SULFONAMIDE SUBSTITUTED HETEROCYCLIC UREA COMPOUNDS | Crestone, Inc. (US) | 2010-06-30 | — | — | EP | claimed |
| WO-2009137404-A1 | UREA COMPOUNDS AS GAMMA SECRETASE MODULATORS | AMGEN INC. (US) | 2009-11-12 | — | — | WO | claimed |
| US-20090163538-A1 | Tetrahydropyridothiophenes For Use In The Treatment Of Cancer | PEKARI KLAUS | 2009-06-25 | — | — | US | claimed |
| US-7517986-B2 | Tetrahydropyridothiophenes for use in the treatment of cancer | 4SC AG (DE) | 2009-04-14 | — | — | US | claimed |
| WO-2009015208-A1 | ANTIBACTERIAL AMIDE AND SULFONAMIDE SUBSTITUTED HETEROCYCLIC UREA COMPOUNDS | REPLIDYNE, INC. (US) | 2009-01-29 | — | — | WO | claimed |
| EP-1756118-B1 | TETRAHYDROPYRIDOTHIOPHENES FOR USE IN THE TREATMENT OF CANCER | NYCOMED GMBH (DE) | 2008-05-28 | — | — | EP | claimed |
| US-20070213360-A1 | Tetrahydropyridothiophenes for Use in the Treatment of Cancer | NYCOMED GMBH (DE) | 2007-09-13 | — | — | US | claimed |
| EP-1756118-A1 | TETRAHYDROPYRIDOTHIOPHENES FOR USE IN THE TREATMENT OF CANCER | Altana Pharma AG (DE) | 2007-02-28 | — | — | EP | claimed |
| WO-2005118592-A1 | TETRAHYDROPYRIDOTHIOPHENES FOR USE IN THE TREATMENT OF CANCER | ALTANA PHARMA AG (DE) | 2005-12-15 | — | — | WO | claimed |
| EP-3089980-B1 | SERINE/THREONINE KINASE INHIBITORS | ARRAY BIOPHARMA INC (US) | 2018-01-31 | — | — | EP | disclosed |
| EP-2200440-B1 | ANTIBACTERIAL AMIDE AND SULFONAMIDE SUBSTITUTED HETEROCYCLIC UREA COMPOUNDS | CRESTONE INC (US) | 2017-07-19 | — | — | EP | disclosed |
| US-9670208-B2 | Serine/threonine kinase inhibitors | ARRAY BIOPHARMA INC. (US) | 2017-06-06 | — | — | US | disclosed |
| US-9560848-B2 | Method and compositions for biofouling deterrence | CLEMSON UNIVERSITY (US) | 2017-02-07 | — | — | US | disclosed |
| EP-3089980-A1 | SERINE/THREONINE KINASE INHIBITORS | Array Biopharma, Inc. (US) | 2016-11-09 | — | — | EP | disclosed |
| US-20160304519-A1 | SERINE/THREONINE KINASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2016-10-20 | — | — | US | disclosed |
| US-9125414-B2 | Pyridine derivatives compounds for controlling invertebrate pests | BASF SE (DE) | 2015-09-08 | — | — | US | disclosed |
| WO-2015103137-A1 | SERINE/THREONINE KINASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2015-07-09 | — | — | WO | disclosed |
| US-8710056-B2 | Pyridazine compounds for controlling invertebrate pests | BASF SE (DE) | 2014-04-29 | — | — | US | disclosed |
| EP-2451808-B1 | PYRIDAZINE COMPOUNDS FOR CONTROLLING INVERTEBRATE PESTS | BASF SE (DE) | 2014-03-26 | — | — | EP | disclosed |
| US-8288371-B2 | Ortho pyrrolidine, benzyl-substituted heterocycle CCR1 antagonists for autoimmune diseases and inflammation | PHARMACOPEIA, LLC (US) | 2012-10-16 | — | — | US | disclosed |
| US-20120122681-A1 | Pyridine Derivatives Compounds for Controlling Invertebrate Pests | BASF SE (DE) | 2012-05-17 | — | — | US | disclosed |
| US-20120110705-A1 | Pyridazine Compounds for Controlling Invertebrate Pests | BASF SE (DE) | 2012-05-03 | — | — | US | disclosed |
| US-8148380-B2 | Antibacterial amide and sulfonamide substituted heterocyclic urea compounds | CRESTONE, INC. (US) | 2012-04-03 | — | — | US | disclosed |
| US-20120015941-A1 | Antibacterial Amide and Sulfonamide Substituted Heterocyclic Urea Compounds | CRESTONE, INC. (US) | 2012-01-19 | — | — | US | disclosed |
| US-20110123477-A1 | METHOD AND COMPOSITIONS FOR BIOFOULING DETERRENCE | NAVY, SECRETARY OF THE UNITED STATES OF AMERICA | 2011-05-26 | — | — | US | disclosed |
| US-20110118234-A1 | Urea Compounds as Gamma Secretase Modulators | AMGEN INC. | 2011-05-19 | — | — | US | disclosed |
| EP-2300427-A1 | UREA COMPOUNDS AS GAMMA SECRETASE MODULATORS | AMGEN INC. (US) | 2011-03-30 | — | — | EP | disclosed |
| EP-2274384-A2 | METHOD AND COMPOSITIONS FOR BIOFOULING DETERRENCE | Clemson University (US) | 2011-01-19 | — | — | EP | disclosed |
| EP-2200440-A1 | ANTIBACTERIAL AMIDE AND SULFONAMIDE SUBSTITUTED HETEROCYCLIC UREA COMPOUNDS | Crestone, Inc. (US) | 2010-06-30 | — | — | EP | disclosed |
| US-20100068211-A1 | USE OF ANTIRESORPTIVE COMPOUNDS TO PREVENT IONIZING RADIATION-INDUCED ACTIVATION OF OSTEOCLASTS AND RESULTING BONE LOSS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2010-03-18 | — | — | US | disclosed |
| WO-2009134303-A9 | METHOD AND COMPOSITIONS FOR BIOFOULING DETERRENCE | CLEMSON UNIVERSITY (US) | 2010-02-18 | — | — | WO | disclosed |
| WO-2009137404-A1 | UREA COMPOUNDS AS GAMMA SECRETASE MODULATORS | AMGEN INC. (US) | 2009-11-12 | — | — | WO | disclosed |
| WO-2009134303-A2 | METHOD AND COMPOSITIONS FOR BIOFOULING DETERRENCE | CLEMSON UNIVERSITY (US) | 2009-11-05 | — | — | WO | disclosed |
| WO-2009082526-A2 | ORTHO PYRROLIDINE, BENZYL-SUBSTITUTED HETEROCYCLE CCR1 ANTAGONISTS FOR AUTOIMMUNE DISEASES & INFLAMMATION | PHARMACOPEIA, INC. (US) | 2009-07-02 | — | — | WO | disclosed |
| US-20090163538-A1 | Tetrahydropyridothiophenes For Use In The Treatment Of Cancer | PEKARI KLAUS | 2009-06-25 | — | — | US | disclosed |
| US-7517986-B2 | Tetrahydropyridothiophenes for use in the treatment of cancer | 4SC AG (DE) | 2009-04-14 | — | — | US | disclosed |
| US-20090093472-A1 | ORTHO PYRROLIDINE, BENZYL-SUBSTITUTED HETEROCYCLE CCR1 ANTAGONISTS FOR AUTOIMMUNE DISEASES & INFLAMMATION | PHARMACOPEIA, INC. (US) | 2009-04-09 | — | — | US | disclosed |
| WO-2009015208-A1 | ANTIBACTERIAL AMIDE AND SULFONAMIDE SUBSTITUTED HETEROCYCLIC UREA COMPOUNDS | REPLIDYNE, INC. (US) | 2009-01-29 | — | — | WO | disclosed |
| WO-2008109104-A1 | BIVALENT INHIBITORS OF AKT PROTEIN KINASE | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2008-09-12 | — | — | WO | disclosed |
| EP-1756118-B1 | TETRAHYDROPYRIDOTHIOPHENES FOR USE IN THE TREATMENT OF CANCER | NYCOMED GMBH (DE) | 2008-05-28 | — | — | EP | disclosed |
| US-20070213360-A1 | Tetrahydropyridothiophenes for Use in the Treatment of Cancer | NYCOMED GMBH (DE) | 2007-09-13 | — | — | US | disclosed |
| EP-1756118-A1 | TETRAHYDROPYRIDOTHIOPHENES FOR USE IN THE TREATMENT OF CANCER | Altana Pharma AG (DE) | 2007-02-28 | — | — | EP | disclosed |
| WO-2005118592-A1 | TETRAHYDROPYRIDOTHIOPHENES FOR USE IN THE TREATMENT OF CANCER | ALTANA PHARMA AG (DE) | 2005-12-15 | — | — | WO | disclosed |
| US-3984427-A | Preparation of vinyl lactones and corresponding Mannich bases | HOFFMANN-LA ROCHE INC. (US) | 1976-10-05 | — | — | US | disclosed |
| US-3984427-A | Preparation of vinyl lactones and corresponding Mannich bases | HOFFMANN-LA ROCHE INC. (US) | 1976-10-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110118234-A1 | Urea Compounds as Gamma Secretase Modulators | BACE1, BACE2, PSEN1 | BRD4 2111/4885BRD2 3041/4885PTGS1 1182/4885 |
| US-20090093472-A1 | ORTHO PYRROLIDINE, BENZYL-SUBSTITUTED HETEROCYCLE CCR1 ANTAGONISTS FOR AUTOIMMUNE DISEASES & INFLAMMATION | CCR1, CCR4, CCR3 | BRD4 83/4885BRD2 223/4885PTGS1 225/4885 |
| US-20120015941-A1 | Antibacterial Amide and Sulfonamide Substituted Heterocyclic Urea Compounds | NAAA, AADAC, RPSA | BRD4 533/4885BRD2 1258/4885PTGS1 2348/4885 |
| US-20120122681-A1 | Pyridine Derivatives Compounds for Controlling Invertebrate Pests | PRXL2A, GRIN2A, CNR2 | BRD4 1982/4885BRD2 541/4885PTGS1 1618/4885 |
| US-20160304519-A1 | SERINE/THREONINE KINASE INHIBITORS | TTBK1, MAP3K1, TNNI3K | BRD4 3750/4885BRD2 4131/4885PTGS1 1316/4885 |
| US-20090163538-A1 | Tetrahydropyridothiophenes For Use In The Treatment Of Cancer | BCL2, BAX, MCL1 | BRD4 152/4885BRD2 884/4885PTGS1 643/4885 |
| US-20120110705-A1 | Pyridazine Compounds for Controlling Invertebrate Pests | CNR2, GRIN2C, GRIN2A | BRD4 999/4885BRD2 350/4885PTGS1 1623/4885 |
| US-20070213360-A1 | Tetrahydropyridothiophenes for Use in the Treatment of Cancer | BCL2, BAX, MCL1 | BRD4 196/4885BRD2 956/4885PTGS1 689/4885 |
| US-20100068211-A1 | USE OF ANTIRESORPTIVE COMPOUNDS TO PREVENT IONIZING RADIATION-INDUCED ACTIVATION OF OSTEOCLASTS AND RESULTING BONE LOSS | CTSA, SOST, CTSB | BRD4 2593/4885BRD2 2392/4885PTGS1 1965/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.